These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

519 related items for PubMed ID: 25714021

  • 21. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, Otani H, Kubo T, Jida M, Ueno T, Ando M, Ogino A, Kiura K, Miyoshi S.
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [Abstract] [Full Text] [Related]

  • 22. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY, Lee KO, Kim M, Song JY, Lee KH, Park J, Chae YJ, Kim YH, Suh KH, Lee GS, Park SB, Kim MS.
    Int J Cancer; 2012 May 15; 130(10):2445-54. PubMed ID: 21732342
    [Abstract] [Full Text] [Related]

  • 23. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 24. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.
    Clin Lung Cancer; 2014 Nov 01; 15(6):411-417.e4. PubMed ID: 25242668
    [Abstract] [Full Text] [Related]

  • 25. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
    Hwang KE, Kwon SJ, Kim YS, Park DS, Kim BR, Yoon KH, Jeong ET, Kim HR.
    Exp Cell Res; 2014 May 01; 323(2):288-96. PubMed ID: 24631288
    [Abstract] [Full Text] [Related]

  • 26. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR, Xu YS, Jin E, Zhu LC, Xia B, Chen XF, Li FZ, Ma SL.
    Acta Pharmacol Sin; 2017 Jan 01; 38(1):100-109. PubMed ID: 27840409
    [Abstract] [Full Text] [Related]

  • 27. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
    Ogino A, Kitao H, Hirano S, Uchida A, Ishiai M, Kozuki T, Takigawa N, Takata M, Kiura K, Tanimoto M.
    Cancer Res; 2007 Aug 15; 67(16):7807-14. PubMed ID: 17699786
    [Abstract] [Full Text] [Related]

  • 28. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J, Hu Q, Zhang X, Zheng J, Xie B, Xu Z, Zhang W.
    Oncol Rep; 2018 Apr 15; 39(4):1783-1792. PubMed ID: 29393480
    [Abstract] [Full Text] [Related]

  • 29. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    J Thorac Oncol; 2015 Jan 15; 10(1):93-101. PubMed ID: 25384171
    [Abstract] [Full Text] [Related]

  • 30. Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
    Zhao BX, Wang J, Song B, Wei H, Lv WP, Tian LM, Li M, Lv S.
    Mol Med Rep; 2015 Apr 15; 11(4):2767-74. PubMed ID: 25483995
    [Abstract] [Full Text] [Related]

  • 31. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z, Huang S, Yu H, Jiang Y, Wang C, Meng Q, Shu X, Sun H, Liu K, Li Y, Ma X.
    Eur J Med Chem; 2017 Jun 16; 133():329-339. PubMed ID: 28395219
    [Abstract] [Full Text] [Related]

  • 32. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct 16; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 33. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T, Zhang G, Smith MA, Lopez AS, Bai Y, Li J, Fang B, Koomen J, Rawal B, Fisher KJ, Chen YA, Kitano M, Morita Y, Yamaguchi H, Shibata K, Okabe T, Okamoto I, Nakagawa K, Haura EB.
    Clin Cancer Res; 2014 Aug 01; 20(15):4059-4074. PubMed ID: 24919575
    [Abstract] [Full Text] [Related]

  • 34. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 01; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 35. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
    Das AK, Sato M, Story MD, Peyton M, Graves R, Redpath S, Girard L, Gazdar AF, Shay JW, Minna JD, Nirodi CS.
    Cancer Res; 2006 Oct 01; 66(19):9601-8. PubMed ID: 17018617
    [Abstract] [Full Text] [Related]

  • 36. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J, Guo F, Du Y, Liu X, Qin Q, Liu X, Yin T, Jiang L, Wang Y.
    Int J Oncol; 2015 May 01; 46(5):2083-95. PubMed ID: 25695284
    [Abstract] [Full Text] [Related]

  • 37. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer.
    Bowles DW, Weickhardt A, Jimeno A.
    Drugs Today (Barc); 2013 Sep 01; 49(9):523-35. PubMed ID: 24086949
    [Abstract] [Full Text] [Related]

  • 38. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W, Li Q, Takeuchi S, Yamada T, Koizumi H, Nakamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.
    Clin Cancer Res; 2012 Mar 15; 18(6):1663-71. PubMed ID: 22317763
    [Abstract] [Full Text] [Related]

  • 39. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL, Fan XX, Wong MP, Jiang ZH, Liu ZQ, Yao XJ, Lu LL, Zhou YL, Yau LF, Tin VP, Liu L.
    Antioxid Redox Signal; 2016 Feb 10; 24(5):263-79. PubMed ID: 26528827
    [Abstract] [Full Text] [Related]

  • 40. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.
    Hashida S, Yamamoto H, Shien K, Miyoshi Y, Ohtsuka T, Suzawa K, Watanabe M, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S, Toyooka S.
    Cancer Sci; 2015 Oct 10; 106(10):1377-84. PubMed ID: 26202045
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.